241 related articles for article (PubMed ID: 11705869)
1. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
[TBL] [Abstract][Full Text] [Related]
3. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
[TBL] [Abstract][Full Text] [Related]
4. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis.
Shimizu Y; Minemura M; Tsukishiro T; Kashii Y; Miyamoto M; Nishimori H; Higuchi K; Watanabe A
Hepatology; 1995 Aug; 22(2):525-31. PubMed ID: 7543436
[TBL] [Abstract][Full Text] [Related]
6. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma.
Omagari K; Honda S; Kadokawa Y; Isomoto H; Takeshima F; Hayashida K; Mizuta Y; Murata I; Kohno S
J Gastroenterol Hepatol; 2004 Jul; 19(7):805-11. PubMed ID: 15209629
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?
Farinati F; Marino D; De Giorgio M; Baldan A; Cantarini M; Cursaro C; Rapaccini G; Del Poggio P; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Bernardi M; Trevisani F
Am J Gastroenterol; 2006 Mar; 101(3):524-32. PubMed ID: 16542289
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.
Huang YH; Chen CH; Chang TT; Chen SC; Wang SY; Lee HS; Lin PW; Huang GT; Sheu JC; Tsai HM; Lee PC; Chau GY; Lui WY; Lee SD; Wu JC
J Gastroenterol Hepatol; 2005 May; 20(5):765-71. PubMed ID: 15853992
[TBL] [Abstract][Full Text] [Related]
10. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators.
Hepatology; 2000 Apr; 31(4):840-5. PubMed ID: 10733537
[TBL] [Abstract][Full Text] [Related]
11. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system.
Farinati F; Rinaldi M; Gianni S; Naccarato R
Cancer; 2000 Dec; 89(11):2266-73. PubMed ID: 11147597
[TBL] [Abstract][Full Text] [Related]
12. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.
Hepatology; 1998 Sep; 28(3):751-5. PubMed ID: 9731568
[TBL] [Abstract][Full Text] [Related]
13. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).
Kudo M; Chung H; Osaki Y
J Gastroenterol; 2003; 38(3):207-15. PubMed ID: 12673442
[TBL] [Abstract][Full Text] [Related]
14. Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma.
Gianni S; Cecchetto A; Altavilla G; Ragazzi R; Bertazzo M; De Giorgio M; Baldan A; Fagiuoli S; Farinati F
J Intern Med; 2005 Apr; 257(4):367-73. PubMed ID: 15788007
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.
Grieco A; Pompili M; Caminiti G; Miele L; Covino M; Alfei B; Rapaccini GL; Gasbarrini G
Gut; 2005 Mar; 54(3):411-8. PubMed ID: 15710992
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
18. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.
Tateishi R; Yoshida H; Shiina S; Imamura H; Hasegawa K; Teratani T; Obi S; Sato S; Koike Y; Fujishima T; Makuuchi M; Omata M
Gut; 2005 Mar; 54(3):419-25. PubMed ID: 15710994
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis.
Nanashima A; Omagari K; Tobinaga S; Shibata K; Sumida Y; Mine M; Morino S; Shibasaki S; Ide N; Shindou H; Nagayasu T
Eur J Surg Oncol; 2005 Oct; 31(8):882-90. PubMed ID: 15993031
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
